CN100529065C - 一种包含bpi基因的重组病毒及含有其的药物组合物及其用途 - Google Patents
一种包含bpi基因的重组病毒及含有其的药物组合物及其用途 Download PDFInfo
- Publication number
- CN100529065C CN100529065C CN200580000538.1A CN200580000538A CN100529065C CN 100529065 C CN100529065 C CN 100529065C CN 200580000538 A CN200580000538 A CN 200580000538A CN 100529065 C CN100529065 C CN 100529065C
- Authority
- CN
- China
- Prior art keywords
- gene
- bpi
- virus
- gnb
- aav2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 108
- 101150043508 BPI gene Proteins 0.000 title claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 141
- 208000015181 infectious disease Diseases 0.000 claims abstract description 47
- 239000012634 fragment Substances 0.000 claims abstract description 45
- 238000001415 gene therapy Methods 0.000 claims abstract description 32
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 31
- 241000124008 Mammalia Species 0.000 claims abstract description 10
- 239000013598 vector Substances 0.000 claims description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 241000702421 Dependoparvovirus Species 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 27
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 26
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 11
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 10
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 10
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 241000701161 unidentified adenovirus Species 0.000 claims description 10
- 101150084750 1 gene Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 241000606701 Rickettsia Species 0.000 claims description 6
- 241000589970 Spirochaetales Species 0.000 claims description 6
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 5
- 108091093088 Amplicon Proteins 0.000 claims description 5
- 230000001177 retroviral effect Effects 0.000 claims description 5
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 24
- 238000002360 preparation method Methods 0.000 abstract description 9
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 3
- 102000018358 immunoglobulin Human genes 0.000 abstract description 3
- 239000013603 viral vector Substances 0.000 abstract description 3
- 101100058588 Homo sapiens BPI gene Proteins 0.000 abstract 4
- 244000052769 pathogen Species 0.000 abstract 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 71
- 241000894006 Bacteria Species 0.000 description 66
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 60
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 60
- 210000002966 serum Anatomy 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 43
- 230000006870 function Effects 0.000 description 40
- 239000002158 endotoxin Substances 0.000 description 31
- 229920006008 lipopolysaccharide Polymers 0.000 description 23
- 230000001665 lethal effect Effects 0.000 description 22
- 238000002156 mixing Methods 0.000 description 22
- 230000003834 intracellular effect Effects 0.000 description 21
- 239000003053 toxin Substances 0.000 description 21
- 231100000765 toxin Toxicity 0.000 description 21
- 108700012359 toxins Proteins 0.000 description 21
- 210000003205 muscle Anatomy 0.000 description 20
- 239000007788 liquid Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 18
- 230000000295 complement effect Effects 0.000 description 17
- 230000009385 viral infection Effects 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 14
- 231100000518 lethal Toxicity 0.000 description 13
- 206010052428 Wound Diseases 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 231100000668 minimum lethal dose Toxicity 0.000 description 12
- 230000009182 swimming Effects 0.000 description 12
- 210000001835 viscera Anatomy 0.000 description 12
- 230000003213 activating effect Effects 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 238000003757 reverse transcription PCR Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000239222 Tachypleus Species 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000002924 anti-infective effect Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 230000008676 import Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 102220023256 rs387907547 Human genes 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000010241 blood sampling Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 210000001539 phagocyte Anatomy 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229960000534 cefuroxime sodium Drugs 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000002070 germicidal effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000001087 myotubule Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000004153 renaturation Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 208000013223 septicemia Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241001529572 Chaceon affinis Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 102220369445 c.668T>C Human genes 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000003622 mature neutrocyte Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 230000014207 opsonization Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 102220023258 rs387907548 Human genes 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000002277 temperature effect Effects 0.000 description 2
- 238000004879 turbidimetry Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 101710197274 ATP-dependent target DNA activator B Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 102000006795 dihydrofolate reductase activity proteins Human genes 0.000 description 1
- 108040000939 dihydrofolate reductase activity proteins Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 208000015706 neuroendocrine disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000013326 plasmid cotransfection Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (12)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410056642 CN1733911A (zh) | 2004-08-13 | 2004-08-13 | 一种包含bpi基因的重组病毒及含有其的药物组合物及其用途 |
CN200410056642.X | 2004-08-13 | ||
PCT/CN2005/000986 WO2006015532A1 (fr) | 2004-08-13 | 2005-07-05 | Virus recombinant comprenant un gene bpi et solution pharmaceutique contenant le virus et qui utilise celui-ci |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1839200A CN1839200A (zh) | 2006-09-27 |
CN100529065C true CN100529065C (zh) | 2009-08-19 |
Family
ID=35839130
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410056642 Withdrawn CN1733911A (zh) | 2004-08-13 | 2004-08-13 | 一种包含bpi基因的重组病毒及含有其的药物组合物及其用途 |
CN200580000538.1A Expired - Fee Related CN100529065C (zh) | 2004-08-13 | 2005-07-05 | 一种包含bpi基因的重组病毒及含有其的药物组合物及其用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410056642 Withdrawn CN1733911A (zh) | 2004-08-13 | 2004-08-13 | 一种包含bpi基因的重组病毒及含有其的药物组合物及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN1733911A (zh) |
WO (1) | WO2006015532A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104745595B (zh) * | 2015-03-27 | 2017-06-27 | 宁波大学 | 刺参bpi基因、编码蛋白及其克隆方法和重组刺参bpi基因工程菌构建方法 |
EP3566717A1 (en) * | 2018-05-09 | 2019-11-13 | Universität Regensburg | Bactericidal/permeability increasing protein for use in a method of immunization, preferably as an adjuvant in a method of vaccination |
CN109762791B (zh) * | 2018-11-19 | 2021-02-09 | 厦门联合安金生物工程有限公司 | 包含BPI-Fc嵌合基因的重组腺病毒及其用途 |
CN109762841B (zh) * | 2018-11-19 | 2021-03-02 | 厦门联合安金生物工程有限公司 | BPI-Fc融合蛋白及其用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1324803A (zh) * | 2000-05-22 | 2001-12-05 | 首都医科大学 | BPI-Fc重组蛋白的高效生产方法及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4382193A (en) * | 1992-05-19 | 1993-12-13 | Xoma Corporation | BPI-immunoglobulin fusion proteins |
-
2004
- 2004-08-13 CN CN 200410056642 patent/CN1733911A/zh not_active Withdrawn
-
2005
- 2005-07-05 WO PCT/CN2005/000986 patent/WO2006015532A1/zh active Application Filing
- 2005-07-05 CN CN200580000538.1A patent/CN100529065C/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1324803A (zh) * | 2000-05-22 | 2001-12-05 | 首都医科大学 | BPI-Fc重组蛋白的高效生产方法及其应用 |
Non-Patent Citations (2)
Title |
---|
腺病毒载体、腺病毒相关病毒载体与基因治疗. 卢大儒等.国外医学遗传学分册,第18卷第2期. 1995 |
腺病毒载体、腺病毒相关病毒载体与基因治疗. 卢大儒等.国外医学遗传学分册,第18卷第2期. 1995 * |
Also Published As
Publication number | Publication date |
---|---|
CN1733911A (zh) | 2006-02-15 |
CN1839200A (zh) | 2006-09-27 |
WO2006015532A1 (fr) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Findlay et al. | Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold | |
Huang et al. | A model for antimicrobial gene therapy: demonstration of human β-defensin 2 antimicrobial activities in vivo | |
Buhtoiarov et al. | Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects | |
CN111892646B (zh) | 抗菌肽衍生物及其在制备抗细菌感染药物中的应用 | |
KR102224929B1 (ko) | 해삼에서 분리한 항균 펩타이드로부터 유래한 신규 항균 펩타이드 및 이의 용도 | |
CN100529065C (zh) | 一种包含bpi基因的重组病毒及含有其的药物组合物及其用途 | |
Zhang et al. | Mammary gland expression of antibacterial peptide genes to inhibit bacterial pathogens causing mastitis | |
CN116042593B (zh) | 产气荚膜梭菌噬菌体裂解酶及其在制备抗产气荚膜梭菌感染药物中的应用 | |
Ma et al. | IL‐24 protects against Salmonella typhimurium infection by stimulating early neutrophil Th1 cytokine production, which in turn activates CD8+ T cells | |
CN106543271A (zh) | 抗耐药性感染多肽Cbf‑14‑2及其用途 | |
Dąbrowska et al. | Bacteriophage pharmacology and immunology | |
CN110393791A (zh) | hnRNPA2B1的抗感染作用及其应用 | |
CN110066342A (zh) | 一种具有免疫调节、中和消解内毒素和抗炎功能的杂合肽及其制备方法与应用 | |
JP4225780B2 (ja) | 低分子量酸可溶性胞子タンパク質およびその使用方法 | |
CN102526703B (zh) | 一种鼻咽癌相关易感基因yh1蛋白的制备方法及其应用 | |
CN110157677A (zh) | 一种靶向性t淋巴细胞及其制备方法和应用 | |
KR102506674B1 (ko) | 항생제 내성균에 대한 항균 활성을 가지는 항균 펩타이드 h103b 및 이의 용도 | |
CN102552306A (zh) | 一种中性粒细胞抗菌肽阻断剂治疗败血症的方法 | |
CN102776264A (zh) | 与凋亡或坏死相关的TNFα短肽及其应用 | |
Yuan et al. | In vitro and in vivo antibacterial activity of a lysine-rich scorpion peptide derivative | |
CN112316115B (zh) | 一种具有抑制恶性肿瘤的蛋白序列及应用 | |
CN111346212A (zh) | 活性多肽在制备抗冠状病毒药物及医用食品中的应用 | |
CN102775496B (zh) | 靶向清除hiv/siv的复合药物 | |
CN101134110B (zh) | Q型非病毒载体以及包含其的药物组合物 | |
CN109536454A (zh) | 工程化改造巨噬细胞及其在脓毒败血症中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161110 Address after: 361028 room 120, technical service center, 1107 Xin Garden Road, Haicang District, Fujian, Xiamen, China Patentee after: XIAMEN LIANHEANJIN BIOTECH Co.,Ltd. Patentee after: Chen Jindong Address before: Beijing City, right outside the West China No. 10 Patentee before: Capital Medical University Patentee before: Chen Jindong |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230826 Address after: 361028 room 1107, technical service center, 120 Xinyuan Road, Haicang District, Xiamen City, Fujian Province Patentee after: XIAMEN LIANHEANJIN BIOTECH Co.,Ltd. Patentee after: ANJUN (BEIJING) GENE TECHNOLOGY Co.,Ltd. Address before: 361028 room 1107, technical service center, 120 Xinyuan Road, Haicang District, Xiamen City, Fujian Province Patentee before: XIAMEN LIANHEANJIN BIOTECH Co.,Ltd. Patentee before: Chen Jindong |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090819 |